Fresh Patents navbar
Monitor Patents Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents Browse Locations

BMY - Bristol-Myers Squibb Company patents

This listing is of recent patents (patent applications) which may be related to Bristol-Myers Squibb Company according to a patent app search. In *most* cases, they are listed under Bristol-Myers Squibb Company because the company is listed in the Agent field of the patent application. Note: Bristol-Myers Squibb Company (BMY) may have other listings under a different name, spelling or agent. If there is another company with a similar name, it's possible their patents could be inadvertantly included here. Notify us of any issues. Also, FreshPatents.com is not affiliated with Bristol-Myers Squibb Company, we're just tracking patents related to them as published publically by the USPTO. Full list of Stock Symbols and Company RSS Feeds

SUBSCRIBE to updates on this page: Bristol-Myers Squibb Company patents RSS Feed (FREE) RSS

B

BA
BAX
BC
BDX
BEC
BHI
BIIB
BLC
BMRN
BMS
BMY
BRCD
BTH
BWA
BZ
Symbol Company Application # Date Title
BMY Bristol-Myers Squibb Company 20120115847 20120510 Compounds for the treatment of hepatitis c
BMY Bristol-Myers Squibb Company 20120114643 20120510 4-pyridinone compounds and their use for cancer
BMY Bristol-Myers Squibb Company 20120108596 20120503 Aza-bicyclic amine n-oxide compounds as alpha-7 nicotinic acetylcholine receptor ligand pro-drugs
BMY Bristol-Myers Squibb Company 20120108594 20120503 Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-n-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide and novel stable forms produced therein
BMY Bristol-Myers Squibb Company 20120101262 20120426 Protein purification by caprylic acid (octanoic acid) precipitation
BMY Bristol-Myers Squibb Company 20120093766 20120419 Compounds for the treatment of hepatitis c
BMY Bristol-Myers Squibb Company 20120093767 20120419 Compounds for the treatment of hepatitis c
BMY Bristol-Myers Squibb Company 20120094909 20120419 Fibronectin based scaffold domain proteins that bind to pcsk9
BMY Bristol-Myers Squibb Company 20120094983 20120419 Acyclic ikur inhibitors
BMY Bristol-Myers Squibb Company 20120095017 20120419 Pharmaceutical formulations of substituted azaindoleoxoacetic piperazine derivatives with protease inhibitors
BMY Bristol-Myers Squibb Company 20120088758 20120412 Five-membered heterocycles useful as serine protease inhibitors
BMY Bristol-Myers Squibb Company 20120088925 20120412 Novel alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
BMY Bristol-Myers Squibb Company 20120077826 20120329 [6,5] - bicyclic gpr119 g protein-coupled receptor agonists
BMY Bristol-Myers Squibb Company 20120077207 20120329 Cd86 and cd80 receptor competition assays
BMY Bristol-Myers Squibb Company 20120071403 20120322 Methods for treating type 2 diabetes in patients resistant to previous treatment with other anti-diabetic drugs employing an sglt2 inhibitor and compositions thereof
BMY Bristol-Myers Squibb Company 20120059019 20120308 Compounds for the treatment of hepatitis c
BMY Bristol-Myers Squibb Company 20120059017 20120308 Cgrp receptor antagonist
BMY Bristol-Myers Squibb Company 20120058996 20120308 Carbazole carboxamide compounds useful as kinase inhibitors
BMY Bristol-Myers Squibb Company 20120058988 20120308 Carbazole and carboline kinase inhibitors
BMY Bristol-Myers Squibb Company 20120052065 20120301 Methods of treatment using ctla4 mutant molecules
BMY Bristol-Myers Squibb Company 20120053130 20120301 Composition for enhancing absorption of a drug and method
BMY Bristol-Myers Squibb Company 20120053145 20120301 Aripiprazole complex formulation and method
BMY Bristol-Myers Squibb Company 20120046294 20120223 Compounds for the treatment of hepatitis c
BMY Bristol-Myers Squibb Company 20120041190 20120216 Macrocycles as factor xia inhibitors
BMY Bristol-Myers Squibb Company 20120035177 20120209 Tablet formulation for p38 inhibitor and method
BMY Bristol-Myers Squibb Company 20120035178 20120209 Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
BMY Bristol-Myers Squibb Company 20120035189 20120209 Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
BMY Bristol-Myers Squibb Company 20120035350 20120209 Polynucleotide encoding a novel human p2x7 splice variant, hbmyp2x7v
BMY Bristol-Myers Squibb Company 20120028994 20120202 Compounds for the reduction of beta-amyloid production
BMY Bristol-Myers Squibb Company 20120027782 20120202 Monoclonal antibody partner molecule conjugates directed to protein tyrosine kinase 7 (ptk7)
BMY Bristol-Myers Squibb Company 20120022041 20120126 Substituted heterocyclic compounds
BMY Bristol-Myers Squibb Company 20120021533 20120126 Sensitive method to analyse free peg-maleimide
BMY Bristol-Myers Squibb Company 20120015438 20120119 Mammallian cell culture process for protein production
BMY Bristol-Myers Squibb Company 20120010402 20120112 Cgrp receptor antagonists
BMY Bristol-Myers Squibb Company 20120010385 20120112 Splice variants of human g-protein coupled receptor hgprbmy29 (hgprmby29sv2)
BMY Bristol-Myers Squibb Company 20110319449 20111229 Pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists
BMY Bristol-Myers Squibb Company 20110319439 20111229 Aza pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists
BMY Bristol-Myers Squibb Company 20110311480 20111222 Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
BMY Bristol-Myers Squibb Company 20110311482 20111222 Hepatitis c virus inhibitors
BMY Bristol-Myers Squibb Company 20110311529 20111222 Method for treating a rheumatic disease using a soluble tla4 molecule
BMY Bristol-Myers Squibb Company 20110305663 20111215 Serum albumin binding molecules
BMY Bristol-Myers Squibb Company 20110294162 20111201 B-7 related nucleic acids and polypeptides useful for immunomodulation
BMY Bristol-Myers Squibb Company 20110294793 20111201 Hydroxyphenyl sulfonamides as antiapoptotic bcl inhibitors
BMY Bristol-Myers Squibb Company 20110294816 20111201 Pyrrolotriazine kinase inhibitors
BMY Bristol-Myers Squibb Company 20110294819 20111201 Hepatitis c virus inhibitors
BMY Bristol-Myers Squibb Company 20110295015 20111201 4-pyridinone compounds and their use for cancer
BMY Bristol-Myers Squibb Company 20110288085 20111124 Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors
BMY Bristol-Myers Squibb Company 20110288051 20111124 Triazolopyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors
BMY Bristol-Myers Squibb Company 20110286961 20111124 Hepatitis c virus inhibitors
BMY Bristol-Myers Squibb Company 20110281910 20111117 Hepatitis c virus inhibitors
BMY Bristol-Myers Squibb Company 20110274648 20111110 Hepatitis c virus inhibitors
BMY Bristol-Myers Squibb Company 20110268697 20111103 Hepatitis c virus inhibitors
BMY Bristol-Myers Squibb Company 20110269139 20111103 Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
BMY Bristol-Myers Squibb Company 20110269787 20111103 Azabicyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands
BMY Bristol-Myers Squibb Company 20110269956 20111103 Hepatitis c virus inhibitors
BMY Bristol-Myers Squibb Company 20110262448 20111027 Human antibodies that bind mesothelin, and uses thereof
BMY Bristol-Myers Squibb Company 20110263494 20111027 Nonsteroidal compounds useful as modulators of glucocorticoid receptor ap-1 and/or nf-kappab acitivity and use thereof
BMY Bristol-Myers Squibb Company 20110263548 20111027 Pyridone and pyridazone analogues as gpr119 modulators
BMY Bristol-Myers Squibb Company 20110263605 20111027 Azabicyclo[2.2.1]heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands
BMY Bristol-Myers Squibb Company 20110257085 20111020 Crystal forms of saxagliptin and processes for preparing same
BMY Bristol-Myers Squibb Company 20110256099 20111020 Compounds for the treatment of hepatitis c
BMY Bristol-Myers Squibb Company 20110250176 20111013 Combinations of hepatitis c virus inhibitors
BMY Bristol-Myers Squibb Company 20110250625 20111013 Gamma secretase notch biomarkers
BMY Bristol-Myers Squibb Company 20110251196 20111013 Modulators of g protein-coupled receptor 88
BMY Bristol-Myers Squibb Company 20110251204 20111013 Modulators of g protein-coupled receptor 88
BMY Bristol-Myers Squibb Company 20110251221 20111013 Pyrimidinylpiperidinyloxypyridinone analogues as gpr119 modulators
BMY Bristol-Myers Squibb Company 20110251223 20111013 Cgrp receptor antagonists
BMY Bristol-Myers Squibb Company 20110245226 20111006 Piperidinyl derivatives as modulators of chemokine receptor activity
BMY Bristol-Myers Squibb Company 20110245227 20111006 Pyridone gpr119 g protein-coupled receptor agonists
BMY Bristol-Myers Squibb Company 20110245241 20111006 Hiv integrase inhibitors
BMY Bristol-Myers Squibb Company 20110245252 20111006 Pyrrolotriazine kinase inhibitors
BMY Bristol-Myers Squibb Company 20110245264 20111006 Modulators of g protein-coupled receptor 88
BMY Bristol-Myers Squibb Company 20110245268 20111006 Pharmaceutical formulations of substituted azaindoleoxoacetic piperazine derivatives with protease inhibitors
BMY Bristol-Myers Squibb Company 20110237636 20110929 Hepatitis c virus inhibitors
BMY Bristol-Myers Squibb Company 20110230468 20110922 Fused heterocyclic compounds and uses thereof
BMY Bristol-Myers Squibb Company 20110230528 20110922 Use of epothilone d in treating tau-associated diseases including alzheimer's disease
BMY Bristol-Myers Squibb Company 20110224199 20110915 Heterocyclic aromatic compounds useful as growth hormone secretagogues
BMY Bristol-Myers Squibb Company 20110217342 20110908 Flashmelt oral dosage formulation
BMY Bristol-Myers Squibb Company 20110212971 20110901 Diketo fused azolopiperidines and azolopiperazines as anti-hiv agents
BMY Bristol-Myers Squibb Company 20110212937 20110901 Compounds for the reduction of beta-amyloid production
BMY Bristol-Myers Squibb Company 20110212930 20110901 Lactam-containing compounds and derivatives thereof as factor xa inhibitors
BMY Bristol-Myers Squibb Company 20110207772 20110825 Glycine chroman-6-sulfonamides for use as inhibitors of diacylglycerol lipase
BMY Bristol-Myers Squibb Company 20110207749 20110825 Glycine chroman-6-sulfonamides for use as inhibitors of diacylglycerol lipase
BMY Bristol-Myers Squibb Company 20110200672 20110818 Coated tablet formulation and method
BMY Bristol-Myers Squibb Company 20110201795 20110818 Methods of producing c-aryl glucoside sglt2 inhibitors
BMY Bristol-Myers Squibb Company 20110195986 20110811 Pyrrolone melanin concentrating hormone receptor-1 antagonists
BMY Bristol-Myers Squibb Company 20110195934 20110811 Azolopyrrolone melanin concentrating hormone receptor-1 antagonists
BMY Bristol-Myers Squibb Company 20110195044 20110811 Hepatitis c virus inhibitors
BMY Bristol-Myers Squibb Company 20110189189 20110804 Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
BMY Bristol-Myers Squibb Company 20110190255 20110804 Heterocyclic compounds
BMY Bristol-Myers Squibb Company 20110190292 20110804 Heterobicyclic compounds useful as kinase inhibitors
BMY Bristol-Myers Squibb Company 20110190327 20110804 Method for modulating gpr119 g protein-coupled receptor and selected compounds
BMY Bristol-Myers Squibb Company 20110172176 20110714 Crystal structures of sglt2 inhibitors and processes for preparing same
BMY Bristol-Myers Squibb Company 20110166154 20110707 Identification of predictive markers of response to dasatinib in human colon cancer
BMY Bristol-Myers Squibb Company 20110166160 20110707 Pyrazinone modulator of corticotropin-releasing factor receptor activity
BMY Bristol-Myers Squibb Company 20110166352 20110707 Process for making sterile aripiprazole of desired mean particle size
BMY Bristol-Myers Squibb Company 20110160224 20110630 Aripiprazole complex formulation and method
BMY Bristol-Myers Squibb Company 20110160220 20110630 Crystalline form of 6-[(4s)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
BMY Bristol-Myers Squibb Company 20110160207 20110630 Heterocyclic amide compounds useful as kinase inhibitors
BMY Bristol-Myers Squibb Company 20110152340 20110623 Methods for identifying subjects with an increased likelihood of responding to dpp-iv inhibitors
BMY Bristol-Myers Squibb Company 20110142835 20110616 Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
BMY Bristol-Myers Squibb Company 20110144060 20110616 Substituted pyrazinone melanin concentrating hormone receptor-1 antagonists and methods
BMY Bristol-Myers Squibb Company 20110136783 20110609 [6,6] and [6,7]-bicyclic gpr119 g protein-coupled receptor agonists
BMY Bristol-Myers Squibb Company 20110130433 20110602 Hepatitis c virus inhibitors
BMY Bristol-Myers Squibb Company 20110123545 20110526 Combination of vegfr2 and igf1r inhibitors for the treatment of proliferative diseases
BMY Bristol-Myers Squibb Company 20110124623 20110526 Pyrrolotriazine kinase inhibitors
BMY Bristol-Myers Squibb Company 20110124640 20110526 Fused heterocyclic compounds useful as kinase modulators
BMY Bristol-Myers Squibb Company 20110124662 20110526 Substituted carbamate derivatives as modulators of corticotropin-releasing factor receptor activity
BMY Bristol-Myers Squibb Company 20110124689 20110526 Process for preparing atazanavir bisulfate and novel forms
BMY Bristol-Myers Squibb Company 20110118354 20110519 Cyclohexenyl modulators of chemokine receptor activity
BMY Bristol-Myers Squibb Company 20110118279 20110519 Pharmaceutical formulations of substituted azaindoleoxoacetic piperazine derivatives with protease inhibitors
BMY Bristol-Myers Squibb Company 20110118211 20110519 Novel glucokinase activators and methods of using same
BMY Bristol-Myers Squibb Company 20110112155 20110512 Methods for treating cancer in patients having breast cancer resistance protein overexpression
BMY Bristol-Myers Squibb Company 20110112146 20110512 Chromene modulators of chemokine receptor activity
BMY Bristol-Myers Squibb Company 20110104315 20110505 Tetrahydroquinoline derivatives as cannabinoid receptor modulators
BMY Bristol-Myers Squibb Company 20110104664 20110505 Biomarkers and methods for determining sensitivity to micortubule-stabilizing agents
BMY Bristol-Myers Squibb Company 20110105485 20110505 Alpha-(n-sulfonamido)acetamide derivatives as beta-amyloid inhibitors
BMY Bristol-Myers Squibb Company 20110105495 20110505 Cyclopentathiophene modulators of the glucocorticoid receptor, ap-1, and/or nf-kb activity and use thereof
BMY Bristol-Myers Squibb Company 20110098467 20110428 Pyrrolo-triazine aniline compounds useful as kinase inhibitors
BMY Bristol-Myers Squibb Company 20110098327 20110428 Hepatitis c virus inhibitors
BMY Bristol-Myers Squibb Company 20110086857 20110414 N-((1r,2s,5r)-5-(tert-butylamino)-2-((s)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes




###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Bristol-Myers Squibb Company in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Bristol-Myers Squibb Company with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

Design/code © 2008 FreshContext LLC/Freshpatents.com. Website Terms and Conditions